首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1634170

全球药物滥用检测市场 - 2025 - 2033

Global Drug Abuse Testing Market - 2025 - 2033

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2023年，全球药物滥用检测市场规模达72.6亿美元，预计2033年将达123.1亿美元，2025-2033年预测期间复合年增长率为5.3%。

药物滥用测试是检测人体系统中的处方药、确保安全性、合规性和医疗评估的关键过程。它用于工作场所筛检、法医调查、体育反兴奋剂措施和临床诊断。它使用尿液、血液、头髮、唾液或汗水等生物样本来识别阿片类药物、安非他明、大麻素、可卡因和苯二氮平类药物等物质。药物滥用日益普遍，增加了药物检测对于预防、介入和公共卫生的重要性。

市场动态：

驱动程式和限制

药物滥用疾病的盛行率上升

由于药物滥用疾病的盛行率不断增加，全球药物滥用检测市场正在蓬勃发展。政府、医疗机构和雇主正在实施强有力的协议来识别和解决成瘾问题。未经治疗的药物滥用造成的社会和经济成本，包括医疗费用、工作场所生产力损失和法律后果，加剧了广泛检测的紧迫性。对先进、可靠的药物检测技术的需求不断增加，导致检测方法的创新和市场的扩大。这凸显了药物滥用检测在缓解全球毒品危机和增强公共卫生方面的关键作用。

例如，根据 2023 年美国国家药物使用与健康调查显示，12 岁及以上的美国人中有 16.7% 患有物质使用障碍，而 10.2% 患有酒精使用障碍。大约 9.7% 的人患有药物使用障碍，2.7% 的人两者都有。此外，7.9% 的成年人在过去一年中同时患有精神健康障碍和药物滥用障碍或併发疾病。

先进药品检测设备成本高

由于先进药物检测设备的成本高昂，全球药物滥用检测市场面临挑战，特别是在低收入地区和规模较小的组织中。 GC-MS 系统和 HPLC 分析仪需要大量的初始投资和持续维护，这使得许多潜在用户无法负担。这种财务障碍限制了综合检测方法的采用，并透过减少资金不足的医疗机构中可靠的药物滥用检测来阻碍市场的成长潜力。

Drug abuse testing is a crucial process for detecting prescription drugs in a person's system, ensuring safety, compliance, and medical evaluation. It is used in workplace screening, forensic investigations, sports anti-doping initiatives, and clinical diagnostics. Using biological samples like urine, blood, hair, saliva, or sweat, it identifies substances like opioids, amphetamines, cannabinoids, cocaine, and benzodiazepines. The increasing prevalence of substance abuse has increased the importance of drug testing for prevention, intervention, and public health.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Substance Abuse Disorders

The global drug abuse testing market is booming due to the increasing prevalence of substance abuse disorders. Governments, healthcare institutions, and employers are implementing robust protocols to identify and address addiction issues. The societal and economic costs of untreated drug abuse, including healthcare expenses, workplace productivity loss, and legal repercussions, have heightened the urgency for widespread testing. The demand for advanced and reliable drug testing technologies has accelerated, leading to innovations in testing methods and expanding the market. This highlights the critical role of drug abuse testing in mitigating the global drug crisis and enhancing public health.

For instance, according to US National Survey on Drug Use and Health 2023 revealed that 16.7% of Americans aged 12 and older had a substance use disorder, while 10.2% had an alcohol use disorder. About 9.7% had a drug use disorder, and 2.7% had both. Additionally, 7.9% of adults had both a mental health disorder and a substance use disorder or co-occurring disorders in the past year.

High Cost of Advanced Drug Testing Equipment

The global drug abuse testing market faces challenges due to the high cost of advanced drug testing equipment, particularly in low-income regions and smaller organizations. GC-MS systems and HPLC analyzers require substantial initial investments and ongoing maintenance, making them less affordable for many potential users. This financial barrier restricts the adoption of comprehensive testing methods and hampers the market's growth potential by reducing reliable drug abuse testing in underfunded healthcare settings.

Segment Analysis

The global drug abuse testing market is segmented based on product type, sample type, end user and region.

Product Type:

Consumables segment is expected to dominate the Drug Abuse Testing market share

The consumables segment holds a major portion of the drug abuse testing market share and is expected to continue to hold a significant portion of the drug abuse testing market share during the forecast period.

Consumables are essential in the global drug abuse testing market, ensuring efficient execution of drug testing procedures. They include test kits, reagents, and sample collection devices, used in various settings like hospitals, clinics, laboratories, workplaces, and at-homes. The high demand for consumables is driven by their recurring use in drug testing and continuous innovation in test kits. As drug abuse testing becomes more widespread, consumption of these essential products increases, making consumables a significant revenue generator. Their role in enhancing efficiency, accuracy, and convenience of drug testing solidifies their importance in the global market.

For instance, in June 2024, FUJIFILM Wako Pure Chemicals Corporation has launched two new tests: LumiMAT Pyrogen Detection Kit (LumiMAT), a next-generation monocyte activation test for in vitro2 pyrogen testing, and PYROSTAR Neo+, a recombinant protein reagent for detecting bacterial endotoxins.

End User:

Hospitals segment is the fastest-growing segment in Drug Abuse Testing market share

The hospitals segment is the fastest-growing segment in the drug abuse testing market share and is expected to hold the market share over the forecast period.

Hospitals are key players in the global drug abuse testing market, providing comprehensive drug testing and treatment. Equipped with advanced diagnostic technologies and trained professionals, they conduct a wide range of tests, from initial screenings to confirmatory tests. They also offer medical interventions for substance abuse issues, including counseling, detoxification, and long-term treatment plans. Hospitals' ability to handle complex cases ensures reliable, accurate, and timely drug testing. Their widespread reach and medical expertise expand the adoption of drug abuse testing in clinical and emergency settings. Hospitals often collaborate with public health organizations, law enforcement, and employers to implement large-scale testing programs, driving demand for drug testing services and consumables.

Geographical Analysis

North America is expected to hold a significant position in the Drug Abuse Testing market share

North America holds a substantial position in the drug abuse testing market and is expected to hold most of the market share due to rising awareness of health risks linked to drug abuse and the need for testing in healthcare, workplace, and law enforcement sectors. The prevalence of substance abuse disorders and high adoption of drug testing technologies in hospitals, clinics, and laboratories contribute to market growth. North America's advanced healthcare infrastructure and well-established systems make it a key player in the market, with significant investments in research, development, and innovation of drug testing products and services.

For instance, in August 2024, Psychemedics Corporation, a global leader in hair testing, has launched a new ketamine hair testing solution, a significant advancement in drug-free workplace detection and prevention.

Moreover, in December 2023, Quest Diagnostics has launched a confirmatory testing service for novel psychoactive substances (NPS), covering 88 compounds across various drug classes. The panel aims to help healthcare providers detect potential drug misuse in patients prescribed controlled medications, such as opioids, amid the proliferation of synthetic or "designer" drugs in the US drug supply. Two of these classes, xylazine and acetyl fentanyl, are accelerating America's overdose crisis.

Europe is growing at the fastest pace in the Drug Abuse Testing market

Europe holds the fastest pace in the drug abuse testing market and is expected to hold most of the market share due to the government initiatives, stricter regulations, and a rise in drug treatment programs. The region's strong healthcare infrastructure and public health campaigns contribute to the demand for accurate testing solutions. Additionally, European countries are investing in research to develop more efficient drug testing solutions, further supporting the market's growth. The demand for accurate and reliable testing solutions is fuelled by the region's strong healthcare infrastructure.

For instance, in August 2023, the Office for Life Sciences, UK has allocated USD 6.24 Billion towards the development of new technologies that modernize testing services. Government efforts also include reducing the rates of deaths and overdoses that result from addictive substances, thus increasing the demand for drug testing solutions.

Competitive Landscape

The major global players in the drug abuse testing market include Siemens Healthcare, Abbott, Thermo Fisher Scientific Inc., LifeSign LLC., MP Biomedicals, Premier Biotech, Inc., MEDACX Ltd, Chromsystems Instruments & Chemicals GmbH, AccuBioTech Co.Ltd., Screen Italia Srl, Paramedical s.r.l among others.

Key Developments

In February 2024, Veriteque USA has partnered with OraSure Technologies to distribute SwabTek surface test kits, a single-use, dry reagent test for narcotics and explosives, alongside its oral fluid drug screening products. This partnership expands OraSure's drug testing portfolio and provides comprehensive solutions for businesses, educators, and security professionals.
In October 2023, Kerala police have introduced a rapid drug screening system called the SoToxa Mobile Test System, which uses saliva samples and provides results in five minutes. The system is currently being trialed in Thiruvananthapuram city and may be expanded to other parts of the state.

Emerging Players

The emerging players in the drug abuse testing market include American Screening Corporation, Inc., Confirm BioSciences, Phamatech, Inc and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global drug abuse testing market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Sample Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Sample Type
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Substance Abuse Disorders
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of Advanced Drug Testing Equipment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Consumables*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Reagents
- 6.2.4. Assay Kits
- 6.2.5. Calibrators and Controls
6.3. Equipment
- 6.3.1. Immunoassay Analyzers
- 6.3.2. Chromatography Instruments
- 6.3.3. Breathalyzers
6.4. Rapid Testing Devices
- 6.4.1. Dip Cards
- 6.4.2. Test Strips
- 6.4.3. Cassettes

7. By Sample Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 7.1.2. Market Attractiveness Index, By Sample Type
7.2. Urine*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Blood
- 7.2.4. Saliva
- 7.2.5. Hair
- 7.2.6. Sweat

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Laboratories
8.4. Forensic Labs
8.5. Home Testing

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Siemens Healthcare*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Abbott Laboratories
11.3. Thermo Fisher Scientific Inc
11.4. LifeSign LLC
11.5. MP Biomedicals
11.6. Premier Biotech, Inc
11.7. MEDACX Ltd
11.8. Chromsystems Instruments & Chemicals GmbH
11.9. AccuBioTech Co.Ltd
11.10. Screen Italia Srl

LIST NOT EXHAUSTIVE